Abstract
Purpose of the study Liver steatosis is a common and important histological finding in hepatitis C, and is associated with an increased progression of the disease. In HIV co-infected patients, steatosis was independently associated with d-drugs, such as stavudine, especially in non-3 HCV genotypes. We investigate the safety of tenofovir disoproxil fumarate (TDF) in determining hepatic steatosis in HIV/HCV coinfected patients.
Highlights
Address: Clinic of Infectious Diseases, Modena, Italy * Corresponding author from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 9–13 November 2008
We investigate the safety of tenofovir disoproxil fumarate (TDF) in determining hepatic steatosis in HIV/HCV coinfected patients
Genotype other than 3 the risk of steatosis was related to fibrosis, use of d4T and older age
Summary
Absence of liver steatosis in HIV-infected patients receiving tenofovir-containing regimen. Address: Clinic of Infectious Diseases, Modena, Italy * Corresponding author from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. Published: 10 November 2008 Journal of the International AIDS Society 2008, 11(Suppl 1):P273 doi:10.1186/1758-2652-11-S1-P273. Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
